Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$9.69
▼ $0.02 (-0.2%)
Market data updated: 09/20 05:45 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$97.27M
Day Range
$9.60 - $10.19
52-Week Range
$3.92 - $19.15
Beta
—
Next Earnings
10.11.2026
Support
$7.39
Resistance
$11.33
ATRA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-19.7% (1Y)
Strengths: 14/28 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 122.5%
Growth
Biggest negative driver
Daily volatility (ATR)
ATR: 7.4% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
56
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
Not enough data yet to generate this synthesis.
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
58
Value
55
Momentum
54
Risk
26
Sentiment
56
Fundamental
56
Institutional
22
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Everyone's writing about Atara Biotherapeutics, Inc.. News trend score: 56. Reason: 3 of the last 8 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
18
🎯 Conviction (vs. Emotion)
45
Psychology
30
Fundamentals
56
Technical
54
Valuation
55
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-4%
Market Narrative
55
Fundamental Reality
45
Narrative Gap
+10
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 79/100
🔴 Weakest match
Gerald M. Loeb — 13/100
Peter Lynch
One Up on Wall Street (1989)
🟢 79
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 75
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 65
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 63
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 56
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 51
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 50
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 49
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 49
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 45
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 32
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 32
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 30
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 13
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (5 bullish · 4 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
29.7%
Net Margin
27.1%
EBITDA Margin
31.4%
ROE
-84.9%
ROA
161.5%
ROIC
—
EPS
$2.61
Cash
$8.48M
Total Debt
—
Current Ratio
0.82
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$9.69
Estimated Fair Value (DCF)
-$102.20
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-63.67M | $-58.42M |
| 2 | 19.4% | $-76.01M | $-63.98M |
| 3 | 13.8% | $-86.46M | $-66.77M |
| 4 | 8.1% | $-93.49M | $-66.23M |
| 5 | 2.5% | $-95.83M | $-62.28M |
Base FCF (last actual year)
$-50.94M
Terminal Value
$-1.51B
Present Value of Terminal Value
$-982.11M
Enterprise Value
$-1.30B
Net Debt
$0
Equity Value
$-1.30B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
-$3.03
Tangible Book Value per Share (Tangible NAV)
-$3.03
Sentiment based on basic keywords (not AI) — 3 positive, 3 neutral, 2 negative out of the last 8 articles.
SeekingAlpha · 15.9.2026
Benzinga · 8.9.2026
Associated Press · 12.8.2026
Business Wire · 12.8.2026
Benzinga · 12.8.2026
Benzinga · 20.7.2026
Investor's Business Daily · 17.6.2026
Business Wire · 12.6.2026
Atara Biotherapeutics, Inc. (ATRA) currently has a StockIQ AI score of 56/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ATRA currently scores 56/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ATRA's technical score is 54/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 122.5%; Free cash flow growth: 26.1%; Net income growth: 138.3%.
Based on the real signals StockIQ computed: ATR: 7.4% of price; Current ratio: 0.82; Calmar: -0.41 (3y annualized return -37.4% / max drawdown 90.7%).
StockIQ has no recorded dividend payment history for ATRA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 7 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Cherry Brian N | Open Market Purchase | 4.9.2026 | 104,166 | +104,166 | $9.60 |
| Nguyen AnhCo | Open Market Sale | 17.8.2026 | 5,062 | -5,062 | $8.08 |
| Nguyen AnhCo | Open Market Sale | 17.8.2026 | 132,775 | -5,062 | $8.08 |
| Redmile Group, LLC | Exercise of Derivative Securities | 22.7.2026 | 101,089 | -101,089 | — |
| Redmile Group, LLC | Exercise of Derivative Securities | 22.7.2026 | 195,211 | +195,211 | — |
| Redmile Group, LLC | Exercise of Derivative Securities | 22.7.2026 | 55,387 | -55,387 | — |
| Redmile Group, LLC | Exercise of Derivative Securities | 22.7.2026 | 38,735 | -38,735 | — |
| Redmile Group, LLC | Tax Withholding in Shares | 22.7.2026 | 60 | -60 | — |
| Redmile Group, LLC | Exercise of Derivative Securities | 22.7.2026 | 636,912 | +195,211 | — |
| Redmile Group, LLC | Tax Withholding in Shares | 22.7.2026 | 636,852 | -60 | — |
| Redmile Group, LLC | Exercise of Derivative Securities | 22.7.2026 | 0 | -55,387 | — |
| Cherry Brian N | Grant/Award from Employer | 11.6.2026 | 24,000 | +24,000 | — |
| Cherry Brian N | Grant/Award from Employer | 11.6.2026 | 62,320 | +24,000 | — |
| Fust Matthew K | Grant/Award from Employer | 9.6.2026 | 12,000 | +12,000 | — |
| HEIDEN WILLIAM K | Grant/Award from Employer | 9.6.2026 | 12,000 | +12,000 | — |
| Ciongoli Gregory Austin | Grant/Award from Employer | 9.6.2026 | 12,000 | +12,000 | — |
| HEIDEN WILLIAM K | Grant/Award from Employer | 9.6.2026 | 34,188 | +12,000 | — |
| Fust Matthew K | Grant/Award from Employer | 9.6.2026 | 30,188 | +12,000 | — |
| Ciongoli Gregory Austin | Grant/Award from Employer | 9.6.2026 | 12,000 | +12,000 | — |
| Nguyen AnhCo | Open Market Sale | 18.5.2026 | 5,241 | -5,241 | $9.13 |
| Grant-Huerta Yanina | Open Market Sale | 18.5.2026 | 2,414 | -2,414 | $9.13 |
| Grant-Huerta Yanina | Open Market Sale | 18.5.2026 | 49,636 | -2,414 | $9.13 |
| Nguyen AnhCo | Open Market Sale | 18.5.2026 | 137,837 | -5,241 | $9.13 |
| Panacea Innovation Ltd | Open Market Sale | 7.5.2026 | 313,446 | -313,446 | $10.10 |
| EcoR1 Capital, LLC | Open Market Purchase | 7.5.2026 | 507,407 | +507,407 | $9.35 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
427,435 shares short as of 2026-08-31 · vs. 536,897 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
47.4% of trading volume this week was short selling, vs. 32.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology